WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at two upcoming investor conferences.
A live webcast of the conference presentations will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event.
About Repligen Corporation
Repligen Corporation is a life sciences tools and technology company that develops and markets highly innovative bioprocessing solutions and systems. Our products enable efficiencies in the process of manufacturing a wide range of biological drugs, including: monoclonal antibodies; recombinant proteins; cell and gene therapies; and vaccines. We are inspiring advances in bioprocessing for the customers we serve around the globe; primarily biopharmaceutical companies and contract development and manufacturing organizations (CDMOs). Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located within the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. we have sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company, see our website at www.repligen.com and follow us on LinkedIn.
Repligen Contact:
Sondra S. Newman
Global Head of Investor Relations
(781) 419-1881
This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$162.51 |
| Daily Change: | 8.15 5.28 |
| Daily Volume: | 660,289 |
| Market Cap: | US$9.150B |
November 04, 2025 October 28, 2025 August 22, 2025 July 31, 2025 July 29, 2025 | |

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load